TG Therapeutics (TGTX)
Commercializes BRIUMVI while developing B-cell therapies for immune-mediated diseases.
Something off on this page? Send us feedback.
Sells BRIUMVI, an infused anti-CD20 therapy for adults with relapsing multiple sclerosis, primarily through U.S. specialty distributors while earning supply, royalty, and support revenue from Neuraxpharm-led markets abroad. Revenue depends overwhelmingly on one product as development expands into new formulations, immune-mediated indications, and azer-cel cell therapy.
Commercializes BRIUMVI, an anti-CD20 antibody approved for adults with relapsing forms of multiple sclerosis. The commercial model combines direct U.S. marketing with sales through specialty distributors; Neuraxpharm commercializes the medicine in several markets outside the United States, generating supply, royalty, and regulatory-support revenue.
Lifecycle development covers a simplified intravenous initiation regimen and a subcutaneous formulation. Clinical programs also test BRIUMVI in myasthenia gravis and treatment-resistant schizophrenia, while azer-cel, an allogeneic CAR T therapy, is being studied in progressive multiple sclerosis and other B-cell disorders.
Revenue remains overwhelmingly tied to U.S. BRIUMVI sales. Manufacturing is outsourced, ublituximab carries licensing royalties, overseas commercialization depends on Neuraxpharm, and pipeline expansion depends on clinical evidence and regulatory approval.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 4, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $70 | Target: $78 |
| Jun 22, 2026 | Jefferies | Reiterate | Rating: —Target: — | Target: $83 |
| May 6, 2026 | H.C. Wainwright | Target | Target: $60 | Target: $70 |
| Jan 14, 2026 | Goldman Sachs | Target | Target: $20 | Target: $39 |
| Oct 6, 2025 | H.C. Wainwright | Target | Target: $55 | Target: $60 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $552.2M · Total debt $754.4M · Total assets $1.64B · Shareholders' equity $604.1M
- Revenue
- $240.3M
- Operating income
- $21.7M
- Net income
- $7.8M
No dividends on record.
| Institutions | 73.56% | 112.59M shares | |
|---|---|---|---|
| 463 holders · as of Jun 30, 2026 | |||
| Insiders | 7.54% | 11.54M shares | |
| 7 holders · as of Sep 14, 2026 | |||
| Strategic holders | 8.25% | 12.63M shares | |
| 1 holder · as of Sep 11, 2020 | |||
| Other | 10.65% | 16.31M shares | |
| remainder | |||
153.07M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 14.41% | 22.05M | as of Jun 30, 2026 |
Ra Capital Management, L.P.Strategic10 percent owner | 8.25% | 12.63M | filed Sep 11, 2020 |
Michael S. WeissInsiderdirector, officer: CEO | 6.39% | 9.78M | filed Jan 9, 2026 |
Vanguard Portfolio Management LLCInstitution | 5.20% | 7.96M | as of Jun 30, 2026 |
State Street CorpInstitution | 5.09% | 7.79M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 10, 2026 | Laurence N. Charney | director | −5,000 | $54.96 |
| Nov 24, 2025 | Yann Echelard | director | −5,000 | $32.57 |
- Novartis (ADR)
Direct self-administered anti-CD20 rival in relapsing MS
- Biogen
Established MS franchise with high-efficacy infusion alternatives
- Bristol-Myers Squibb
Oral S1P RMS alternative competing with infusion anti-CD20 therapy
- Sanofi (ADR)
Established RMS DMTs plus BTK pressure in progressive MS
- Johnson & Johnson
Oral ponesimod option in relapsing MS treatment selection
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| TG Therapeutics | $56.61 | −2.58% | $8.90B | 21.2 | 29.8 | 11.1 | +70.3% |
| Novartis (ADR) | $142.46 | +0.83% | $268.53B | 21.3 | 15.2 | 4.8 | +0.9% |
| Biogen | $224.75 | −0.27% | $33.30B | 39.9 | 17.0 | 3.3 | +3.4% |
| Bristol-Myers Squibb | $61.67 | −0.94% | $127.16B | 13.7 | 9.7 | 2.6 | +5.7% |
| Sanofi (ADR) | $41.63 | −2.08% | $102.08B | 76.0 | — | 1.8 | +11.2% |
| Johnson & Johnson | $270.04 | +0.32% | $648.72B | 31.2 | 22.8 | 6.6 | +6.6% |
| Median | 31.2 | 16.1 | 3.3 | +5.7% |